scholarly journals Pre-intervention clinical determinants and measured β-cell function as predictors of type 2 diabetes remission after Roux-en-Y gastric bypass surgery

2021 ◽  
Author(s):  
Chanel Ligon ◽  
Ankit Shah ◽  
Malini Prasad ◽  
Blandine Laferrère
Keyword(s):  
Type 2 Diabetes ◽  
Bypass Surgery ◽  
Cell Function ◽  
Gastric Bypass Surgery ◽  
Diabetes Remission ◽  
Β Cell ◽  
Β Cell Function ◽  
Clinical Models ◽  
One Year

<u>Background:</u> Bariatric surgery results in improved glycemic control in individuals with type 2 diabetes. Single and clusters of clinical determinants have been identified as pre-surgery predictors of post-surgery diabetes remission. Our goal was to assess if the addition of measured pre-operative ß-cell function would improve established clinical models of prediction of diabetes remission. <p><u>Methods:</u> Pre-surgery clinical characteristics, metabolic markers, and ß-cell function after oral and intravenous (IV) glucose challenges were assessed in 73 individuals with severe obesity and type 2 diabetes and again one year after gastric bypass surgery. Single and multivariate analyses were conducted with pre-operative variables to determine best predictive models of remission.</p> <p><u>Results:</u> Pre-surgery ß-cell glucose sensitivity, a surrogate of ß-cell function, was negatively correlated with known diabetes duration, HbA1c, insulin use, and the diabetes remission scores DiaRem and Ad-DiaRem (all p <0.001). Measured ß-cell function after oral glucose was 1.6-fold greater than after IV glucose challenge, and more strongly correlated with pre-operative clinical and metabolic characteristics. The addition of pre-operative ß-cell function to clinical models containing well-defined diabetes remission scores did not improve the model’s ability to predict diabetes remission post-RYGB. </p> <p><u>Conclusions:</u> The addition of measured β-cell function does not add predictive value to defined clinical models of diabetes remission one year after surgical weight loss.</p>

scholarly journals Pre-intervention clinical determinants and measured β-cell function as predictors of type 2 diabetes remission after Roux-en-Y gastric bypass surgery

2021 ◽  
Author(s):  
Chanel Ligon ◽  
Ankit Shah ◽  
Malini Prasad ◽  
Blandine Laferrère
Keyword(s):  
Type 2 Diabetes ◽  
Bypass Surgery ◽  
Cell Function ◽  
Gastric Bypass Surgery ◽  
Diabetes Remission ◽  
Β Cell ◽  
Β Cell Function ◽  
Clinical Models ◽  
One Year

<u>Background:</u> Bariatric surgery results in improved glycemic control in individuals with type 2 diabetes. Single and clusters of clinical determinants have been identified as pre-surgery predictors of post-surgery diabetes remission. Our goal was to assess if the addition of measured pre-operative ß-cell function would improve established clinical models of prediction of diabetes remission. <p><u>Methods:</u> Pre-surgery clinical characteristics, metabolic markers, and ß-cell function after oral and intravenous (IV) glucose challenges were assessed in 73 individuals with severe obesity and type 2 diabetes and again one year after gastric bypass surgery. Single and multivariate analyses were conducted with pre-operative variables to determine best predictive models of remission.</p> <p><u>Results:</u> Pre-surgery ß-cell glucose sensitivity, a surrogate of ß-cell function, was negatively correlated with known diabetes duration, HbA1c, insulin use, and the diabetes remission scores DiaRem and Ad-DiaRem (all p <0.001). Measured ß-cell function after oral glucose was 1.6-fold greater than after IV glucose challenge, and more strongly correlated with pre-operative clinical and metabolic characteristics. The addition of pre-operative ß-cell function to clinical models containing well-defined diabetes remission scores did not improve the model’s ability to predict diabetes remission post-RYGB. </p> <p><u>Conclusions:</u> The addition of measured β-cell function does not add predictive value to defined clinical models of diabetes remission one year after surgical weight loss.</p>

scholarly journals Preoperative β-cell function in patients with type 2 diabetes is important for the outcome of Roux-en-Y gastric bypass surgery

2015 ◽  
Vol 593 (14) ◽  
pp. 3123-3133 ◽  
Author(s):  
Michael Taulo Lund ◽  
Merethe Hansen ◽  
Stinna Skaaby ◽  
Sina Dalby ◽  
Mikael Støckel ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Gastric Bypass ◽  
Bypass Surgery ◽  
Cell Function ◽  
Gastric Bypass Surgery ◽  
Β Cell ◽  
Β Cell Function

Gastrointestinal hormones and β-cell function after gastric bypass and sleeve gastrectomy: an RCT (Oseberg)

2021 ◽  
Author(s):  
Farhat Fatima ◽  
Jøran Hjelmesæth ◽  
Kåre Inge Birkeland ◽  
Gulseth Løvdal Hanne ◽  
Jens Kristoffer Hertel ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Gastric Bypass ◽  
Sleeve Gastrectomy ◽  
Cell Function ◽  
Gastrointestinal Hormones ◽  
Diabetes Remission ◽  
Β Cell ◽  
Post Surgery ◽  
Β Cell Function

Abstract Context Whether Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) differentially affect postprandial gastrointestinal hormones and β-cell function in type 2 diabetes remains unclear. Objective To compare gastrointestinal hormones and β-cell function assessed by an oral glucose tolerance test (OGTT) 5 weeks and 1 year after surgery hypothesizing higher GLP-1 levels and greater β-cell response to glucose after RYGB than after SG. Design, Setting, Patients, and Interventions Randomized, triple blind, single-center trial at a tertiary care center in Norway. Primary outcomes; diabetes remission and IVGTT derived β-cell function. Participants with obesity and type 2 diabetes allocated (1:1) to RYGB or SG. Main outcome measures Gastrointestinal hormone profiles and insulin secretion [β-cell glucose sensitivity (β-GS)] derived from 180 minutes OGTTs. Results 106 patients (67% women), mean (SD) age 48 (10) years. Diabetes remission rates at 1-year were higher after RYGB than after SG, 77% versus 48%, p = 0.002. Incremental area under the curve (iAUC0-180) glucagon-like peptide-1 (GLP-1) and β-GS increased more after RYGB than after SG, 1-year between-group difference 1173 pmol/l*min (95% CI 569 to 1776), p = 0.0010, and 0.45 pmol/kg/min/mmol (95% CI 0.15 to 0.75), p = 0.0032, respectively. Post-surgery, fasting and postprandial ghrelin levels were higher and decremental AUC0-180 ghrelin, iAUC0-180 glucose-dependent insulinotropic polypeptide, and iAUC0-60 glucagon were greater after RYGB than after SG. Diabetes remission at 1 year was associated with higher β-GS and higher GLP-1 secretion. Conclusions RYGB was associated with greater improvement in β-cell function and higher postprandial GLP-1 levels than SG.

scholarly journals Serum Amylase Levels in Relation to Islet β Cell Function in Patients with Early Type 2 Diabetes

PLoS ONE ◽  
2016 ◽  
Vol 11 (9) ◽  
pp. e0162204 ◽  
Author(s):  
Lei Zhuang ◽  
Jian-bin Su ◽  
Xiu-lin Zhang ◽  
Hai-yan Huang ◽  
Li-hua Zhao ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Serum Amylase ◽  
Cell Function ◽  
Early Type ◽  
Β Cell ◽  
Β Cell Function
Sign in / Sign up

Export Citation Format

Share Document